Skip to content

Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy

Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03059264
Acronym
TREAT-CDM
Enrollment
100
Registered
2017-02-23
Start date
2016-12-14
Completion date
2025-01-27
Last updated
2025-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Myotonic Dystrophy

Brief summary

Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused by a trinucleotide repeat expansion (CTGn) in the DMPK gene. CDM occurs when the CTGn increases between the adult myotonic dystrophy type-1 (DM1) parent and the child. Children with CDM present at birth with respiratory insufficiency, talipes equinovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As children grow, they are at risk for intellectual impairment, autistic features, gastrointestinal symptoms, and motor delay. The investigators will enroll children with CDM between ages 0-15 with visits at baseline and one year to evaluate appropriate physical functional outcomes, cognitive function and quality of life over time. Functional outcome measures will be correlated with potential biomarkers in the children. Completion of these specific aims will extend the understanding of disease progression in CDM and will provide the requisite information for successful therapeutic trials in children with DM.

Interventions

Longitudinal disease progression

Sponsors

Fondazione Serena Onlus - Centro Clinico NeMO Milano
CollaboratorOTHER
University of Western Ontario, Canada, Children's Health Research Institute
CollaboratorUNKNOWN
Virginia Commonwealth University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 15 Years
Healthy volunteers
Yes

Inclusion criteria

CDM Group Inclusion Criteria: * Age 0-15 yrs * Diagnosis of CDM, based on symptoms and genetic testing of expanded trinucleotide repeats.

Exclusion criteria

* Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of site investigator * Significant trauma within one month * Internal metal or devices Control Group Inclusion Criteria: * Age 0-15 yrs * Healthy children on no medication

Design outcomes

Primary

MeasureTime frameDescription
Grip Strength1 yearMeasure of force generated by hand grip

Secondary

MeasureTime frameDescription
Congenital and Childhood Onset Myotonic Dystrophy Health Index (CCMDHI)1 yearDisease specific patient and parent reported outcome measure of quality of life
6-minute walk1 yearAssess distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance
Behavior Rating Inventory of Executive Function (BRIEF)1 yearAn 86-item parent/caregiver-proxy and teacher-proxy rating form of executive function skills in every-day settings such as school, home, and social situations
Lip Force1 yearMeasure of force generation by orbicularis oris

Countries

Canada, Italy, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026